Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?

被引:32
|
作者
Prihantono [1 ]
Faruk, Muhammad [1 ]
机构
[1] Hasanuddin Univ, Fac Med, Dept Surg, Jalan Perintis Kemerdekaan KM 11, Makassar 90245, South Sulawesi, Indonesia
来源
关键词
Breast cancer; Chemotherapy; Chemoresistance; Biomarkers; Assays; RECEIVING NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; MULTIDRUG-RESISTANCE; RESIDUAL DISEASE; DRUG-RESISTANCE; CLINICAL EXAMINATION; TUMOR RESPONSE; SOLID TUMORS; MAMMOGRAPHY; ACCURACY;
D O I
10.1016/j.amsu.2021.102793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chemotherapy is an essential treatment for breast cancer, inducing cancer cell death. However, chemoresistance is a problem that limits the effectiveness of chemotherapy. Many factors influence chemoresistance, including drug inactivation, changes in drug targets, overexpression of ABC transporters, epithelial-to-mesenchymal transitions, apoptotic dysregulation, and cancer stem cells. The effectiveness of chemotherapy can be assessed clinically and pathologically. Clinical response evaluation is based on physical examination or imaging (mammography, ultrasonography, computed tomography scan, or magnetic resonance imaging) and includes tumor size changes after chemotherapy. Pathological response evaluation is a method based on tumor residues in histopathological preparations. We should be suspicious of chemoresistance if there are no significant changes clinically according to the Response Evaluation Criteria in Solid Tumors and World Health Organization criteria or pathological changes according to the Miller and Payne criteria, especially after 2-3 cycles of chemotherapy treatments. Chemoresistance is mostly detected after the administration of chemotherapy drugs. No reliable parameters or biomarkers can predict chemotherapy responses appropriately and effectively. Well-known parameters such as cancer type, grade, subtype, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and MDR-1/P-gP have been used for selecting chemotherapy regimens. Some new methods for predicting chemoresistance include chemosensitivity and chemoresistance assays, multigene expressions, and positron emission tomography assays. The latest approaches are based on evaluation of molecular processes and the metabolic activity of cancer cells. Some methods for preventing chemoresistance include using the right regimen, using some combination of chemotherapy methods, conducting adequate monitoring, and using drugs that could prevent the emergence of multidrug resistance.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] WHEN AND HOW SHOULD WE VISUALIZE
    KOVERMAN, HC
    [J]. PROFESSIONAL GEOGRAPHER, 1961, 13 (04): : 26 - 27
  • [22] Should we prevent colorectal cancer?
    Tarraga Lopez, Pedro J.
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2011, 103 (10) : 503 - 507
  • [23] Commentary: We can prevent postesophagectomy atrial fibrillation, but should we?
    Hassan, Omar F.
    Weksler, Benny
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 158 (01): : 311 - 312
  • [24] How can we prevent colorectal cancer with ursodeoxycholic acid?
    Arguelles-Arias, F.
    Herrerias-Gutierrez, J. M.
    [J]. INTESTINAL INFLAMMATION AND COLORECTAL CANCER, 2007, 158 : 201 - 206
  • [25] AXILLARY LYMPHOSCINTIGRAPHY FOR BREAST-CANCER - SHOULD WE DO IT - CAN WE DO IT
    HAYES, DF
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1990, 31 (11) : 1835 - 1838
  • [26] Should we warn against night shifts to prevent breast cancer?
    Kolstad, H. A.
    Erlandsen, M.
    Frost, P.
    Bonde, J. P.
    [J]. OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2010, 67 (11) : 797 - 797
  • [27] RESPONSE: Should We Prevent Death When Death Is Preventable, or Should We Just Stand There?
    Crawford, Thomas C.
    Eagle, Kim A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (06) : 695 - 696
  • [28] Can we trust our gut feeling when we suspect child abuse?
    Janson, Staffan
    [J]. ACTA PAEDIATRICA, 2021, 110 (06) : 1713 - 1714
  • [29] How we can modify the risk of breast cancer?
    Zbucka, Monika
    Lesniewska, Monika
    Knapp, Pawel
    Wolczynski, Slawomir
    [J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2005, 4 (06): : 70 - 75
  • [30] When can we suspect of acquired hemophilia A (AHA) at patient?
    Andelkovic, Ana
    Ilic, Jordanka
    Josic, Brankica
    [J]. ANESTHESIA AND ANALGESIA, 2021, 133 (3S_SUPPL): : 1315 - 1315